Breast-specific gamma imaging (BSGI) provider Dilon Diagnostics said that new research shows its gamma camera can perform molecular breast imaging (MBI) at half of the normal radiation dose by halving the amount of radiotracer, with no loss of diagnostic ability.
In a prospective trial performed by Dr. Marcela Bohm-Velez at Weinstein Imaging Associates in Pittsburgh, 72 patients underwent low-dose MBI followed by imaging at the standard dose. Low-dose MBI provided the same diagnostic yield as the images created using the normal dose, Dilon said.
The method is particularly effective in women with dense breasts in whom mammography can miss important lesions, the company said.
Dilon is preparing to submit results for peer-reviewed publication this fall.
